Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2025-03-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
董事会对独董独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a statement from the board of directors regarding the independence of the company's independent directors. It discusses self-assessment and evaluation of the independent directors' independence in accordance with regulatory requirements. There is no financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, no capital changes, and no other report types. The content focuses on governance and compliance with independence rules for directors, which fits the category of Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is Governance Information (CGR).
2025-03-28 Chinese
关于盈康生命科技股份有限公司非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory report regarding non-operating fund occupation and other related party fund transactions for Yingkang Life Technology Co., Ltd. for the year 2024. It includes an audit opinion issued by Hexin Certified Public Accountants (a CPA firm) dated March 27, 2025, referencing the 2024 financial statements audit. The document contains detailed tables summarizing related party fund transactions and non-operating fund occupation, which are supplementary disclosures related to the audited financial statements. The document is not a full annual report (10-K), nor is it a general audit report (AR) because it focuses specifically on related party fund transactions and non-operating fund occupation, which is a specialized audit disclosure. It is not a regulatory filing or announcement of a report, but an actual audit-related explanatory report with detailed data. Given the nature and content, this fits best under Audit Report / Information (AR), as it is a standalone audit-related report focusing on specific audit findings and disclosures related to funds and related party transactions, supported by an audit opinion. The document length (4518 characters) is sufficient to contain substantive content, not just an announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-03-28 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company Yingkang Life Technology Co., Ltd. It references a new accounting standard issued by the Ministry of Finance of China and explains the impact of this change on the company's financial statements. The document does not contain full financial statements or comprehensive financial performance data but rather explains the nature and impact of the accounting policy change. It is a formal announcement to inform shareholders and the public about the accounting policy change, not a full annual or interim report. Given the content and length (1731 characters), it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-28 Chinese
独立董事2024年度述职报告（姜峰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Yingkang Life Technology Co., Ltd. It details the independent director's qualifications, attendance at board and shareholder meetings, committee work, communication with auditors, and oversight activities during the 2024 fiscal year. It includes detailed descriptions of the director's duties, opinions on company governance, related party transactions, financial report disclosures, and stock incentive plans. The document is a comprehensive report on the independent director's annual duties and activities rather than a general annual report or financial statement. It is not a proxy statement, remuneration report, or regulatory filing. The content aligns with a management or board-related report focusing on governance and director responsibilities. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-03-28 Chinese
关于对会计师事务所2024年度履职情况评估的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report evaluating the performance of the accounting firm (auditor) for the fiscal year 2024. It discusses the auditor's qualifications, audit procedures, quality control, and overall assessment of the auditor's work for the company's 2024 annual audit. The content focuses on the auditor's role and performance rather than presenting the company's financial statements or results. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and evaluations of accounting firms' performance. The document is not an Annual Report (10-K) or an Interim Report (IR) because it does not contain financial statements or comprehensive company financial performance data. It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content rather than just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2024
2025-03-28 Chinese
关于苏州广慈肿瘤医院有限公司2024年度承诺业绩实现情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a verification report (鉴证报告) issued by an accounting firm regarding the performance commitment realization of Suzhou Guangci Oncology Hospital Co., Ltd. for the year 2024. It references compliance with the China Securities Regulatory Commission's rules on major asset restructuring and includes detailed financial performance data related to a specific acquisition transaction. The document is not a full annual or interim report but a standalone audit/verification report focused on the achievement of performance commitments tied to a major asset acquisition. It contains audit opinions, accounting procedures, and a conclusion on the performance commitment realization. The document length is 3341 characters, which is relatively short but contains substantive audit content rather than just an announcement. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2024
2025-03-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.